Galapagos begins GLPG1205 Phase I study for inflammatory disorders
According to the agreement signed in 2007, the commencement of the study triggered €6.6m milestone payment from Janssen to Galapagos, which will conduct even Phase IIA studies. Designed
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.